Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics ( (AU:ATH) ) just unveiled an update.
Alterity Therapeutics Limited has announced the quotation of 95,238 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 16, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing research and development initiatives, potentially strengthening its position in the biotech sector and providing value to its stakeholders.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on developing therapeutic solutions for neurodegenerative diseases. The company is primarily engaged in creating treatments for conditions such as Alzheimer’s and Parkinson’s disease, aiming to address significant unmet medical needs in this market.
YTD Price Performance: 50.0%
Average Trading Volume: 15,778,615
Technical Sentiment Signal: Sell
Current Market Cap: A$138.1M
For detailed information about ATH stock, go to TipRanks’ Stock Analysis page.